Ignite Creation Date:
2024-05-06 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 12:01 PM
Study NCT ID:
NCT02752035
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-12
First Post:
2016-04-22
Brief Title:
A Study of ASP2215 Gilteritinib by Itself ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
Sponsor:
Astellas Pharma Global Development Inc
Organization:
Astellas Pharma Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-08-01
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2016-04-22
First Submit QC Date:
April 25 2016
Study First Post Date:
2016-04-26
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
2024-03-07
Disp First Submit QC Date:
March 7 2024
Disp First Post Date:
2024-03-12
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2024-10-11
Last Update Post Date:
2024-06-12
Last Update Post Date Type:
ACTUAL